We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
351
Bicycle Therapeutics
BCYC
$255M
$343K 0.08%
80,789
+44,188
+121% +$203K
ARDC
352
Are Dynamic Credit Allocation Fund
ARDC
$288M
$342K 0.08%
27,117
-7,218
-21% -$90.6K
MLTX icon
353
MoonLake Immunotherapeutics
MLTX
$1.06B
$341K 0.08%
17,507
-929
-5% -$16.8K
RLMD icon
354
Relmada Therapeutics
RLMD
$450M
$340K 0.08%
+49,202
New +$344K
SMMT icon
355
Summit Therapeutics
SMMT
$13.8B
$340K 0.08%
23,355
+7,836
+50% +$139K
CABA icon
356
Cabaletta Bio
CABA
$422M
$338K 0.08%
+108,703
New +$358K
INBX icon
357
Inhibrx
INBX
$1.5B
$336K 0.08%
3,549
+124
+4% +$12.4K
ARCC icon
358
Ares Capital
ARCC
$13.9B
$335K 0.08%
18,080
-5,805
-24% -$108K
TNGX icon
359
Tango Therapeutics
TNGX
$3.94B
$331K 0.08%
10,576
-18,587
-64% -$460K
CBIO
360
Crescent Biopharma
CBIO
$638M
$329K 0.08%
+18,258
New +$356K
NCDL icon
361
Nuveen Churchill Direct Lending
NCDL
$600M
$325K 0.08%
26,180
-2,382
-8% -$31.7K
WVE icon
362
Wave Life Sciences
WVE
$887M
$324K 0.08%
55,741
+39,276
+239% +$260K
BBOT
363
BridgeBio Oncology
BBOT
$382M
$322K 0.08%
+42,220
New +$352K
OFS icon
364
OFS Capital
OFS
$53.5M
$319K 0.07%
90,189
-2,476
-3% -$9.06K
OXSQ icon
365
Oxford Square Capital
OXSQ
$138M
$316K 0.07%
239,321
+25,833
+12% +$41.4K
BTX
366
BlackRock Technology and Private Equity Term Trust
BTX
$1.01B
$314K 0.07%
34,761
-49,545
-59% -$412K
BSL
367
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$169M
$313K 0.07%
24,177
-7,582
-24% -$98.7K
BGB
368
Blackstone Strategic Credit 2027 Term Fund
BGB
$501M
$310K 0.07%
27,390
-7,785
-22% -$88K
CAPR icon
369
Capricor Therapeutics
CAPR
$498M
$305K 0.07%
12,682
+2,203
+21% +$66.8K
SEPN
370
Septerna Inc
SEPN
$1.79B
$305K 0.07%
9,102
-1,617
-15% -$45.9K
BCIC
371
BCP Investment Corp
BCIC
$86.9M
$290K 0.07%
39,887
+7,057
+21% +$54.1K
WHF icon
372
WhiteHorse Finance
WHF
$157M
$279K 0.06%
41,578
-18,988
-31% -$135K
MAIN icon
373
Main Street Capital
MAIN
$5.26B
$268K 0.06%
5,161
-219
-4% -$11.5K
TPVG icon
374
TriplePoint Venture Growth BDC
TPVG
$197M
$262K 0.06%
53,323
-15,190
-22% -$81.4K
EVMN
375
Evommune Inc
EVMN
$340M
$219K 0.05%
+16,500
New +$383K
13 14
15
16 17

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.